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presenting with ST-segment elevation myocardial infarction: a case 
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Abstract   
Background: Multiple thrombi are likely to develop in Coronavirus disease 2019 (COVID-19) patients. Hence, 
achieving successful outcomes following catheterization becomes quite challenging in such patients. 
Case presentation: A 36-year-old female presented with ST-segment elevation myocardial infarction (STEMI). 
Coronary angiography revealed multiple irregularities in the coronary tree as well as thrombi. Although computed 
tomography imaging of the thorax was normal, reverse transcription-polymerase chain reaction (RT-PCR) confirmed 
the diagnosis of COVID-19. The outcome was good TIMI flow after a successful primary angioplasty in acute 
myocardial infarction (PAMI), and the patient was isolated and then switched to oral anticoagulants (clopidogrel) for 
dual antiplatelet therapy (DAPT) therapy. 
Conclusion: This case emphasizes the management of a COVID-19 patient for PAMI. 
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Background  
On March 11, 2020, World Health Organization (WHO) 
proclaimed the novel coronavirus disease (COVID-19) outbreak 
a global pandemic [1]. Although respiratory tract infections are 
typical symptoms and signs of COVID-19, cardiovascular 
manifestations including microvascular and macrovascular 
thrombi most frequently appear in COVID-19 patients. These 
thrombi can lead to multi-organ system injury, and failure [2], 
hence timely detection and prompt management are of utmost 
importance. Here, we reported a unique ST-segment elevation 
myocardial infarction (STEMI) case that abruptly manifested 
into multiple thrombi due to COVID-19. 
  
Case Report     
A 36-year-old female presented to the Emergency Department 
of HCG Hospitals, Ahmedabad- Gujarat, India, on 8 May 2021 
with a three-day history of chest pain. The patient had an 
unremarkable medical history. On arrival, her blood pressure 
was 120/80 mmHg, and her pulse rate was over 100 beats per  
 
 
minute. Laboratory values signified low lymphocyte count and 
elevated High-Sensitivity Cardiac Troponin-I (hscTn-I). 
Echocardiography revealed an absence of Regional Wall 
Motion Abnormality (RWMA). The patient had unexplained 
tachycardia without pulmonary congestion and an S3 gallop. 
Coronary angiography displayed a mild diffuse lesion in the 
Right Coronary Artery (RCA), Left Circumflex (LCX) lesion 
step down in the reference diameter of the main vessel artery 
after proximal LCX, and Left Anterior Descending Artery 
(LAD) - First Diagonal Artery (D1) bifurcation lesion with 
medina class (1,1,1). It further revealed multiple irregularities in 
the coronary tree with thrombus (Fig 1).  
       It was planned to perform PAMI of the LAD artery. On 
account of low lymphocyte count, multiple vessel segments 
were harboring thrombus-like lesions and unexplained 
tachycardia without pulmonary congestion and an S3 gallop. 
We considered the possibility of COVID-19. The patient was 
advised for Real-Time Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR) for Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2). The result of RT-PCR was 
positive; however, computed tomography imaging of the thorax 
was normal. In light of RT-PCR findings, a definitive diagnosis 
of COVID-19 was made. Under stringent precautions, the 
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PAMI was started. LAD was pre-dilated with a short-length 
balloon. Then, a 3 x 32 mm drug-eluting stent (DES) stent was 
implanted, followed by post-dilation with a short-length 
balloon. The final angiography report showed impressive 
outcomes in terms of good TIMI flow.  
After the PAMI procedure, the patient was isolated and then 
switched to clopidogrel (novel oral anticoagulants) from 
ticagrelor/prasugrel for Dual Antiplatelet Therapy (DAPT) 
therapy. 
 
 
Fig 1. (a) Coronary angiography showing mild diffused lesion in the right coronary artery, (b) Coronary angiography showing left circumflex lesion to step down in the 
reference diameter of the main vessel artery after proximal LCX, (c) Coronary angiography showing LAD-D1 bifurcation lesion with medina class (1,1,1), (d) Implantation 
of a 3 x 32 mm DES following pre-dilation of LAD with a short length balloon, (e) post-dilation of the stent with a short length balloon. 
 
 
Discussion 
In this case, low lymphocyte count, multiple vessel segments 
harboring thrombus-like lesions, and unexplained tachycardia 
without pulmonary congestion and S3 gallop raised doubt for 
COVID-19. Since the outbreak of COVID-19 across the world, 
numerous studies have demonstrated a correlation between the 
severity of COVID-19 and lymphopenia, a condition described 
by abnormally low counts of lymphocytes [3-5]. At present, the 
molecular mechanisms of COVID-19 related thrombi have 
gained more attention; nevertheless, the exact mechanism 
behind it is still obscure. It is assumed to be an elevated level of 
pro-inflammatory cytokines [6], which activate the coagulation 
cascade and inhibit fibrinolysis. A procoagulant state in 
COVID-19 is preliminarily caused by Tumor Necrosis Factor-
Alpha (TNF-α), Interferon-Gamma (IFN-γ), and Interleukin-1 
(IL-1). This procoagulant state can result in migration and 
adhesion of leukocytes, activation and adhesion of platelet, and 
endothelial dysfunction, which leads to thrombus formation [7]. 
Numerous studies have recently revealed elevated thrombus 
formation in COVID-19 patients without previous cardiac 
diseases [8, 9]. Choudry et al. [7] described an exciting finding 
of higher thrombus burden in patients presenting with STEMI 
and concomitant COVID-19 infection. To the best of our 
knowledge, the present case is the second reported case of 
multiple irregularities and thrombus in the coronary tree of a 
STEMI patient with COVID-19 infection simultaneously. 
Effect of COVID-19 on STEMI patients could be either direct 
with a high risk of developing acute heart failure or indirect via 
the elevated delay between first medical contact and primary 
percutaneous coronary intervention on account of the recent  
 
 
contamination measures for COVID-19 that are followed by 
tertiary-care centers [10]. Nevertheless, it is assumed that the 
worst clinical scenario could be a combination of COVID-19 
and STEMI in the same patient. However, we achieved 
promising outcomes in such a complex case. We recommend 
using a potent new generation of P2Y12 inhibitors such as 
prasugrel to prevent acute stent thrombosis and achieve 
promising outcomes following PAMI. In light of the ongoing 
COVID-19 pandemic, as per our recommendation, more 
emphasis should be given to maximize the protection of 
healthcare personnel as well as the hospital environment during 
any catheterization procedure. We strictly/strongly recommend 
adherence to guidelines that have been released by the Joint 
venture of The Society for Cardiovascular Angiography and 
Interventions (SCAI), the American College of Cardiology 
(ACC), and the American College of Emergency Physicians 
(ACEP) for the care of patients with STEMI during the 
COVID-19 pandemic [11].  The present case brought to light 
the probability of delaying door-to-Balloon (D2B) time due to 
cautious management of COVID-19 patients. Such a dealy can 
be avoided by competent staff as well as timely pre-operative 
planning. Our motto to inspire other physicians and achieve 
success is "not spend time but invest it."  
 
Conclusion  
This case highlights the effectiveness of PAMI as the standard 
of care for patients suffering from STEMI and COVID-19 
simultaneously. The authors emphasize strict adherence to 
COVID-19 guidelines during catheterization procedures as per 
expert consensus. 
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Abbreviation  
STEMI: ST-Segment Elevation Myocardial Infarction; PAMI: Primary 
Angioplasty in Acute Myocardial Infarction; TIMI: Thrombolysis in 
Myocardial Infarction; WHO: World Health Organization; COVID-19: 
Novel Coronavirus Disease; hscTn-I: High-Sensitivity Cardiac 
Troponin-I; RWMA: Regional Wall Motion Abnormality; RCA: Right 
Coronary Artery; LCX: Left Circumflex; D1: First Diagonal Artery; 
RT-PCR: Real-Time Reverse Transcriptase Polymerase Chain 
Reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome 
Coronavirus-2; TNF-α: Tumor Necrosis Factor-Alpha; IFN-γ: 
Interferon-Gamma; IL-1: Interleukin-1; SCAI: Society for 
Cardiovascular Angiography and Interventions; ACC: American 
College of Cardiology; ACEP: American College of Emergency 
Physicians; D2B: Door-to-Balloon. 
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